| 1 | 10061 | LAO-PA015 | ETCTN | Solid Tumor | Active | A Phase 1 Study of Pembrolizumab (MK-3475) in Combination with Recombinant Interleukin-12 in Patients with Solid Tumors | I | 36/36 | N/A | INTERVENTION |
| 2 | 10146 | LAO-CT018 | ETCTN | Breast Cancer | Active | Randomized Phase 2 Clinical Trial of Nab-Paclitaxel + Durvalumab (MEDI4736) + Tremelimumab + Neoantigen Vaccine Vs. Nab-Paclitaxel + Durvalumab (MEDI4736) + Tremelimumab in Patients with Metastatic Triple Negative Breast Cancer | II | 20/70 | N/A | INTERVENTION |
| 3 | 10222 | LAO-CT018 | ETCTN | Gastrointestinal Cancer;Solid Tumor | Temporarily Closed to Accrual | A Phase II Study of Olaparib and AZD6738 in Isocitrate Dehydrogenase (IDH) Mutant Solid Tumors | II | 24/50 | N/A | INTERVENTION |
| 4 | 10273 | LAO-CA043 | ETCTN | Leukemia | Active | A Phase I Study of M3814 in Combination with MEC in Patients with Relapsed or Refractory Acute Myeloid Leukemia | I | 18/48 | N/A | INTERVENTION |
| 5 | 10287 | LAO-CT018 | ETCTN | Breast Cancer | Active | A Randomized Phase I/II Trial of Fulvestrant and Abemaciclib in Combination with Copanlisib (FAC) Versus Fulvestrant and Abemaciclib Alone (FA) for Endocrine-Resistant, Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer (FAC vs FA) | I/II | 24/24 | N/A | INTERVENTION |
| 6 | 10292 | LAO-NCI | ETCTN | Solid Tumor | Active | DURVA+ : Evaluation of the Safety and Pharmacodynamics of Anti-PD-L1 Antibody Durvalumab in Combination with Chemotherapy in Patients with Advanced Solid Tumors | II | 69/115 | N/A | INTERVENTION |
| 7 | 10301 | LAO-CT018 | ETCTN | Male Reproductive System Cancer | Active | A Phase I and Randomized Phase II Trial of Radium-223 Dichloride, M3814, & Avelumab in Advanced Metastatic Castrate-Resistant Prostate Cancer (mCRPC) | I/II | 15/24 | N/A | INTERVENTION |
| 8 | 10330 | LAO-CT018 | ETCTN | Bone Cancer | Temporarily Closed to Accrual | A Phase 2 Study of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma | II | 19/32 | N/A | INTERVENTION |
| 9 | 10406 | LAO-PA015 | ETCTN | Gastrointestinal Cancer | Active | Phase I/Ib Trial of ATR Inhibitor BAY 1895344 in Combination with FOLFIRI in GI Malignancies with a Focus on Metastatic Colorectal and Gastric/Gastroesophageal Cancers | I | 7/90 | N/A | INTERVENTION |
| 10 | 10504 | LAO-NCI | ETCTN | Soft Tissue Cancer/Sarcoma | Active | A Randomized Phase 2 Study of Atezolizumab with or Without Selinexor in Alveolar Soft Part Sarcoma (AXIOM) | II | 6/77 | N/A | INTERVENTION |
| 11 | 10505 | LAO-CA043 | ETCTN | CNS Cancer (Primary tumor) | Active | A Phase 1 and Randomized Phase 2 Trial of Selinexor and Temozolomide in Recurrent Glioblastoma | I/II | 3/24 | N/A | INTERVENTION |
| 12 | 10507 | LAO-MA036 | ETCTN | Miscellaneous and Metastatic Cancer | Active | A Phase 1/2 Study of the Bromodomain Inhibitor ZEN003694 in Combination with Etoposide/Platinum in Patients with NUT Carcinoma | I/II | 7/18 | N/A | INTERVENTION |
| 13 | 10517 | LAO-11030 | ETCTN | Urothelial/ Bladder Cancer | Active | An Open Label, Randomized Phase II Study Neoadjuvant Erdafitinib with or Without Atezolizumab in Cisplatin-Ineligible Patients with Muscle Invasive Bladder Cancer (NERA) | II | 0/44 | N/A | INTERVENTION |
| 14 | 10527 | LAO-MA036 | ETCTN | Solid Tumor | Temporarily Closed to Accrual | A Molecularly Driven Phase 1b Dose Escalation and Dose Expansion Study of the DNA-PK Inhibitor Peposertib (M3814) in Combination with the ATR Inhibitor M1774 | I | 0/66 | N/A | INTERVENTION |
| 15 | A021806 | ALLIANCE | NCTN | Gastrointestinal Cancer | Active | A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer | III | 182/352 | N/A | INTERVENTION |
| 16 | A021901 | ALLIANCE | NCTN | Endocrine Cancer | Active | Randomized Phase II Trial of Lutetium Lu 177 Dotatate Versus Everolimus in Somatostatin Receptor Positive Bronchial Neuroendocrine Tumors | II | 5/108 | N/A | INTERVENTION |
| 17 | A051902 | ALLIANCE | NCTN | Lymphoma | Active | A Randomized Phase II Study of CHO(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-Cell Lymphomas | II | 15/182 | N/A | INTERVENTION |
| 18 | A071401 | ALLIANCE | NCTN | CNS Cancer (Primary tumor) | Active | Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas with SMO/ AKT/ NF2/CDK Pathway Mutations | II | 85/124 | 435 | SCREENING, INTERVENTION |
| 19 | A091802 | ALLIANCE | NCTN | Skin Cancer | Active | Phase II Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma of the Skin (cSCC) | II | 58/59 | N/A | INTERVENTION |
| 20 | A091903 | ALLIANCE | NCTN | Skin Cancer | Active | A Randomized Phase II Trial of Adjuvant Nivolumab with or Without Cabozantinib in Patients with Resected Mucosal Melanoma | II | 17/99 | N/A | INTERVENTION |
| 21 | A211801 | ALLIANCE | NCORP | N/A | Active | BRCA-P: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, International Phase 3 Study to determine the Preventive Effect of Denosumab on Breast Cancer in Women carrying a BRCA1 Germline Mutation | III | 11/300 | N/A | INTERVENTION |
| 22 | A212102 | ALLIANCE | NCORP | Miscellaneous and Metastatic Cancer | Active | Blinded Reference Set For Multicancer Early Detection Blood Tests | Other | N/A | N/A | OTHER |
| 23 | AMC-112 | AMC | MISCELLANEOUS | AIDS-related Malignancy and Condition | Temporarily Closed to Accrual | Axicabtagene Ciloleucel in Relapsed or Refractory HIV-Associated Aggressive B-Cell Non-Hodgkin Lymphoma | I | 0/20 | 0 | SCREENING, INTERVENTION |
| 24 | ANHL2121 | COG | NCTN | Hematopoietic Neoplasm (excluding Leukemia, Lymphoma and Myeloma) | Active | Phase 2 Study of Tovorafenib (DAY101) in Relapsed and Refractory Langerhans Cell Histiocytosis | II | 0/29 | N/A | INTERVENTION |
| 25 | DCP-001 | DCP | NCORP | Hematopoietic Neoplasm (excluding Leukemia, Lymphoma and Myeloma);Solid Tumor | Active | Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP) | Other | N/A | N/A | OTHER |
| 26 | EA1181 | ECOG-ACRIN | NCTN | Breast Cancer | Active | EA1181 (CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response Part 1 Component of: The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer) | II | 2037/2156 | N/A | INTERVENTION |
| 27 | EA1211 | ECOG-ACRIN | NCTN | Breast Cancer | Active | Interim FDG-PET/CT for PreDIcting REsponse of HER2+ Breast Cancer to Neoadjuvant Therapy: DIRECT Trial | II | 0/235 | N/A | INTERVENTION |
| 28 | EA2174 | ECOG-ACRIN | NCTN | Gastrointestinal Cancer | Temporarily Closed to Accrual | A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma | II/III | 275/278 | N/A | INTERVENTION |
| 29 | EA2176 | ECOG-ACRIN | NCTN | Gastrointestinal Cancer | Active | A Randomized Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Naive Metastatic Anal Cancer Patients | III | 118/205 | N/A | INTERVENTION |
| 30 | EA2192 | ECOG-ACRIN | NCTN | Gastrointestinal Cancer | Active | APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation | II | 36/152 | N/A | INTERVENTION |
| 31 | EA6141 | ECOG-ACRIN | NCTN | Skin Cancer | Active | Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma | II/III | 421/601 | N/A | INTERVENTION |
| 32 | EA8134 | ECOG-ACRIN | NCTN | Male Reproductive System Cancer | Active | InPACT- International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study) | III | 74/200 | N/A | INTERVENTION |
| 33 | EA8192 | ECOG-ACRIN | NCTN | Urothelial/ Bladder Cancer | Active | A Phase II/III Trial of Durvalumab and Chemotherapy for Patients with High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy | II/III | 19/249 | N/A | INTERVENTION |
| 34 | EA8212 | ECOG-ACRIN | NCTN | Urothelial/ Bladder Cancer | Active | A Randomized Phase III Trial of Intravesical BCG VeRsus Intravesical Docetaxel and GEmcitabine Treatment in BCG Naïve High Grade Non-Muscle Invasive Bladder Cancer (BRIDGE) | III | 72/870 | N/A | INTERVENTION |
| 35 | EAA173 | ECOG-ACRIN | NCTN | Myeloma | Active | Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) | III | 142/288 | N/A | INTERVENTION |
| 36 | EAY191 | ECOG-ACRIN | NCTN | Lymphoma;Solid Tumor | Active | Molecular Analysis for Combination Therapy Choice (ComboMATCH) | Other | N/A | 5 | SCREENING |
| 37 | NRG-BR008 | NRG | NCTN | Breast Cancer | Active | A Phase III Randomized Trial of Radiotherapy Optimization for Low-Risk HER2-Positive Breast Cancer (HERO*) *Her2 Radiation Optimization (HERO) | III | 1/1300 | N/A | INTERVENTION |
| 38 | NRG-GU012 | NRG | NCTN | Kidney Cancer | Active | Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI) | II | 1/240 | N/A | INTERVENTION |
| 39 | NRG-GY022 | NRG | NCTN | Solid Tumor | Active | Assessment of Carboplatin Clearance Predictors: A PK Study on NCI-Sponsored Clinical Trials or Standard of Care Treatments Using Carboplatin | I | 240/350 | N/A | INTERVENTION |
| 40 | PEPN2111 | PEP-CTN | MISCELLANEOUS | Bone Cancer;CNS Cancer (Primary tumor);Lymphoma;Solid Tumor | Temporarily Closed to Accrual | A Phase 1/2 Trial of CBL0137 (NSC# 825802) in Patients with Relapsed or Refractory Solid Tumors Including CNS Tumors and Lymphoma | I/II | 9/38 | N/A | INTERVENTION |
| 41 | S0820 | SWOG | NCORP | Gastrointestinal Cancer | Active | A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III- Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES) | III | 350/389 | N/A | INTERVENTION |
| 42 | S1501 | SWOG | NCORP | Breast Cancer | Active | Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III | III | 297/817 | 316 | SCREENING, INTERVENTION |
| 43 | S1914 | SWOG | NCTN | Lung, Mediastinal, and Pleural Cancer | Active | A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC | III | 214/480 | N/A | INTERVENTION |
| 44 | S1933 | SWOG | NCTN | Lung, Mediastinal, and Pleural Cancer | Active | A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients with Borderline Performance Status | II | 29/47 | N/A | INTERVENTION |
| 45 | S1937 | SWOG | NCTN | Urothelial/ Bladder Cancer | Temporarily Closed to Accrual | A Phase III Randomized Trial of Eribulin (NSC #707389) with or Without Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy | III | 23/465 | N/A | INTERVENTION |
| 46 | S2005 | SWOG | NCTN | Lymphoma | Temporarily Closed to Accrual | A Phase II Randomized Study of Ibrutinib and Rituximab with or Without Venetoclax in Previously Untreated Waldenström's Macroglobulinemia (WM) / Lymphoplasmacytic Lymphoma (LPL) | II | 1/62 | N/A | INTERVENTION |
| 47 | S2012 | SWOG | NCTN | Endocrine Cancer | Active | Randomized Phase II/III Trial of First Line Platinum/Etoposide with or Without Atezolizumab (NSC#783608) in Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC) | II/III | 14/189 | N/A | INTERVENTION |
| 48 | S2013 | SWOG | NCORP | N/A | Active | Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study | Other | N/A | N/A | OTHER |
| 49 | S2209 | SWOG | NCTN | Myeloma | Active | A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a Subset of "Intermediate Fit" Comparing Upfront Three-Drug Induction Regimens Followed by Double or Single-Agent Maintenance | III | 0/510 | N/A | INTERVENTION |
| 50 | 10184 | LAO-NCI | ETCTN | Head and Neck Cancer | Active | Birinapant and Intensity Modulated Re-Irradiation Therapy (IMRRT) for Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) | I | 10/34 | N/A | INTERVENTION |